may

AMN Healthcare to Hold First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025

DALLAS, April 08, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss…

2 days ago

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

March 27, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) --…

2 weeks ago

Fortune to Host First Most Powerful Women International Summit in Riyadh, Saudi Arabia, May 20-21, 2025

Fortune to unveil the 100 Most Powerful Women in Business list on May 20 The Most Powerful Women International Summit…

2 weeks ago

Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more…

3 weeks ago

Las Vegas News Briefs May 2024

ENTERTAINMENTSAM HUNT TO PERFORM AT FONTAINEBLEAU LAS VEGAS IN OCTOBER 2024Country superstar Sam Hunt is coming to BleauLive Theater inside…

2 months ago

Purchasers of Quantstamp QSP Tokens May Be Eligible for Payment from the Quantstamp Fair Fund

COSTA MESA, Calif., Jan. 22, 2025 /PRNewswire/ -- The following statement is being issued by Simpluris, Inc., the SEC-appointed Fund Administrator.…

3 months ago

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…

5 months ago

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…

5 months ago

New Meta-Analysis Strengthens Evidence That Nuts May Lower Cardiovascular Risk

BARCELONA, Spain, Nov. 6, 2024 /PRNewswire/ -- A recent systematic review and meta-analysis funded by the International Nut and Dried…

5 months ago

New Meta-Analysis Strengthens Evidence That Nuts May Lower Cardiovascular Risk

BARCELONA, Spain, Nov. 6, 2024 /PRNewswire/ -- A recent systematic review and meta-analysis funded by the International Nut and Dried…

5 months ago